Macroaxis: Personalized Investing  
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
 US Market Open: Feb 8, 14:12 PM 2012 
  NYSE  8068.30  1.41  Index Moved Down   NASDAQ  2906.83  2.75  Index Moved Up 
 and more..
Search
sponsered by
  
  



Processing
Collecting necessary data for SLXP...
48.92
  
Salix Quote
Intraday
 
Salix Intraday Quote
One Month
 0.49   Macroaxis: 1.01 Up   1.01%  
 25.64 Year To Date 50.28 
 48.33 Trading Day  49.09 
    
Diversification Suggestion
Use Salix to enhance returns of your portfolios. The stock experiences large bullish trend
1 Month Beta vs NYSE ......... -0.33
As returns on NYSE increase, returns on owning Salix are expected to decrease at a much smaller rate. During bear market, Salix is likely to outperform the market
Salix Almost negative beta
    
SLXP Macroaxis: United States NASDAQSalix Quote: Bull
Salix Pharmaceuticals Ltd.
http://www.salix.com
919-862-1000
Trade Salix
Run Report
 Run Report 
Correlation
 Correlation 
Drugs - Generic  
Market Capitalization 2.893B  
Earnings Per Share 1.30  
Today Lowest 48.33  
Book Value Per Share 8.127  
 Carolyn J. Logan  executive  Carolyn J. Logan
Chief Officer, President, Director 
 Adam C. Derbyshire  executive  Adam C. Derbyshire
Chief Financial Officer, Principal  
Dr. William P. Forbes Pharm. D. executive Dr. William P. Forbes Pharm. D.
Chief Devel. Officer and VP of R&a 
Dr. Lorin K. Johnson Ph.D. executive Dr. Lorin K. Johnson Ph.D.
Co-Founder and Chief Scientific Lia 
 Randy W. Hamilton  executive  Randy W. Hamilton
Co-Founder 

Salix fundamentals

    
P/E37.25Open48.74
P/B Ratio5.96Volume236267
SectorHealthcareLast Close48.43
Short Ratio7.80Last Traded2/8/2012
Year High50.28Percent ChangePrice Moved Up 1.01%
Year Low25.64Absolute Change0.49 Price Moved Up
EPS1.30Index MembershipNot Applicable
PEG Ratio0.93Employees390
Day High49.09Day Low48.33
Target Price54.53Current EPS1.30
This Year EPS2.53Next Year EPS2.78
Current PE37.25This Year PE19.14
Next Year PE17.42DividendNot Applicable
    

Salix Performance    Embed Financials for Salix Pharmaceuticals  Ltd.

    
    
 Embed Financials for Salix Pharmaceuticals  Ltd.

Salix Profile

    
Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs for the treatment of gastrointestinal disorders in the United States.
 Macroaxis: thisGreen SLXP   1.01 % Macroaxis: change 1.01 Moved Up  
 
 Macroaxis: United States IXIC   0.09 % Macroaxis: 0.09 Moved Up  
 
 Macroaxis: United States GSPC   0.01 % Macroaxis: 0.01 Moved Down  
 
 Macroaxis: United States NYA   0.02 % Macroaxis: 0.02 Moved Down  
 
 Live Sentiment  
 Bulls COST 
 NASDAQ Macroaxis: United States 
 Bought few shares of
 23 minutes ago
for 84.56 
 Bulls PEP 
 NYSE Macroaxis: United States 
 Bought few shares of
 23 minutes ago
for 66.76 
 Bulls UPS 
 NYSE Macroaxis: United States 
 Bought few shares of
 23 minutes ago
for 77.29 
 Bulls QCOM 
 NASDAQ Macroaxis: United States 
 Bought few shares of
 23 minutes ago
for 61.55 
 Bulls ATVI 
 NASDAQ Macroaxis: United States 
 Bought over 70 shares of
 23 minutes ago
for 12.44 
    

Salix 30-Days Moving Rating

    

Macroaxis Total Score 

    
0
Current 30 Days Moving Rating
    
    

Estimated Market Risk

 1.75
  actual daily
 
 71 %
of total potential
 
Market Risk score

Expected Return

 -0.02
  actual daily
 
 1 %
of total potential
 
Expected Return score

Risk-Adjusted Return

 -0.01
  actual daily
 
 1 %
of total potential
 
Risk-Adjusted Return score
Based on monthly moving average   [ change ] 
Increase Risk-Adjusted return of SLXP by adding it to a well-diversified portfolio
    

 Salix Last Intraday

    
 
0.49Macroaxis: 0.49 Down1.01%
 
48.43,48.43,48.92,48.92,48.33,49.09,48.92
 
48.4348.92
    

Latest headlines for Salix


Salix Pharmaceuticals (SLXP) Downgraded by Stifel Nicolaus to "Hold"

LocalizedUSA - Jan 30, 2012 Salix Pharmaceuticals (NASDAQ: SLXP) was downgraded by Stifel Nicolaus from a ?buy? rating to a ?hold? rating in a research note issued on Monday. Salix Pharmaceuticals Up 2.6% Since JMP Securities Downgraded One Week Ago (SLXP) - Financial News Network Online

Salix Pharmaceuticals Up 2.6% Since JMP Securities Downgraded One Week Ago (SLXP)

A week ago, JMP Securities downgraded Salix Pharmaceuticals from Outperform to Market Perform. The shares closed at $47.29, or 2.6% over the $46.11 price of one week ago.

Salix Pharmaceuticals is Among the Companies in the Pharmaceuticals Industry ...

Salix Pharmaceuticals is Among the Companies in the Pharmaceuticals Industry ... Financial News Network Online - 10 hours ago We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength.

Salix Pharmaceuticals is Among the Companies in the Pharmaceuticals Industry ...

Salix Pharmaceuticals is Among the Companies in the Pharmaceuticals Industry ... Financial News Network Online - 10 hours ago We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength.

Downgrade Alert for Salix Pharmaceuticals (SLXP)

Jan 23, 2012 (SmarTrend(R) Upgrades/Downgrades via COMTEX) -- Salix Pharmaceuticals (SLXP) was downgraded from Outperform to Market Perform at JMP Securities today. Salix Pharmaceuticals (SLXP) Shares Downgraded to "Market Perform" by JMP ... - LocalizedUSA